Biotech News
Supernus Announces Third Quarter 2025 Financial Results
ir.supernus.com2026-05-06 15:28 EST
Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024. This strong growth was driven by an increase in net sales of Qelbree ® and GOCOVRI ® , and the addition of sales from ZURZUVAE ® and ONAPGO™.